CD155 in Bladder Cancer

Fudan University

Status: Enrolling

Conditions: Bladder Cancer

Treatments: Drug: Adjuvant chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT03789682

FUSCC-URO1201-2018-1

Details and patient eligibility

About

This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with non-metastatic muscle invasive bladder cancer
• pathology confirmed urothelial carcinoma
• underwent cystectomy and pelvic lymph node dissection

Exclusion criteria

• not enough tissue for immunohistochemistry
• patients with a second neoplasm

Trial design

150 participants in 1 patient group

FUSCC cystectomy cohort

Description:

patients underwent cystectomy in Fudan University Shanghai Cancer Center

Treatment:

Drug: Adjuvant chemotherapy